Global Hepatitis B Vaccine (Recombinant) Market Research Report 2021

Publisher Name :
Date: 23-Mar-2021
No. of pages: 93
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- 10mcg/0.5ml

- 10mcg/ml

Segment by Application

- Newborn

- Adult

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

By Company

- GSK

- Merck

- Sanofi Pasteur

- Dynavax Technologies

- LG Life Sciences

- KM Biologics

- Shenzhen Kangtai Biological Products

- Serum Institute

Global Hepatitis B Vaccine (Recombinant) Market Research Report 2021

Table of Contents
1 Hepatitis B Vaccine (Recombinant) Market Overview
1.1 Product Overview and Scope of Hepatitis B Vaccine (Recombinant)
1.2 Hepatitis B Vaccine (Recombinant) Segment by Type
1.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 10mcg/0.5ml
1.2.3 10mcg/ml
1.3 Hepatitis B Vaccine (Recombinant) Segment by Application
1.3.1 Hepatitis B Vaccine (Recombinant) Sales Comparison by Application: (2021-2027)
1.3.2 Newborn
1.3.3 Adult
1.4 Global Hepatitis B Vaccine (Recombinant) Market Size Estimates and Forecasts
1.4.1 Global Hepatitis B Vaccine (Recombinant) Revenue 2016-2027
1.4.2 Global Hepatitis B Vaccine (Recombinant) Sales 2016-2027
1.4.3 Hepatitis B Vaccine (Recombinant) Market Size by Region: 2016 Versus 2021 Versus 2027
2 Hepatitis B Vaccine (Recombinant) Market Competition by Manufacturers
2.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2016-2021)
2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Hepatitis B Vaccine (Recombinant) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Hepatitis B Vaccine (Recombinant) Manufacturing Sites, Area Served, Product Type
2.5 Hepatitis B Vaccine (Recombinant) Market Competitive Situation and Trends
2.5.1 Hepatitis B Vaccine (Recombinant) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Hepatitis B Vaccine (Recombinant) Players Market Share by Revenue
2.5.3 Global Hepatitis B Vaccine (Recombinant) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hepatitis B Vaccine (Recombinant) Retrospective Market Scenario by Region
3.1 Global Hepatitis B Vaccine (Recombinant) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Hepatitis B Vaccine (Recombinant) Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.3.1 North America Hepatitis B Vaccine (Recombinant) Sales by Country
3.3.2 North America Hepatitis B Vaccine (Recombinant) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.4.1 Europe Hepatitis B Vaccine (Recombinant) Sales by Country
3.4.2 Europe Hepatitis B Vaccine (Recombinant) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Region
3.5.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region
3.5.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.6.1 Latin America Hepatitis B Vaccine (Recombinant) Sales by Country
3.6.2 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.7.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country
3.7.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Hepatitis B Vaccine (Recombinant) Historic Market Analysis by Type
4.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2016-2021)
4.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2016-2021)
4.3 Global Hepatitis B Vaccine (Recombinant) Price by Type (2016-2021)
5 Global Hepatitis B Vaccine (Recombinant) Historic Market Analysis by Application
5.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2016-2021)
5.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2016-2021)
5.3 Global Hepatitis B Vaccine (Recombinant) Price by Application (2016-2021)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 GSK Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Merck Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Sanofi Pasteur Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Dynavax Technologies
6.4.1 Dynavax Technologies Corporation Information
6.4.2 Dynavax Technologies Description and Business Overview
6.4.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Dynavax Technologies Product Portfolio
6.4.5 Dynavax Technologies Recent Developments/Updates
6.5 LG Life Sciences
6.5.1 LG Life Sciences Corporation Information
6.5.2 LG Life Sciences Description and Business Overview
6.5.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 LG Life Sciences Product Portfolio
6.5.5 LG Life Sciences Recent Developments/Updates
6.6 KM Biologics
6.6.1 KM Biologics Corporation Information
6.6.2 KM Biologics Description and Business Overview
6.6.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.6.4 KM Biologics Product Portfolio
6.6.5 KM Biologics Recent Developments/Updates
6.7 Shenzhen Kangtai Biological Products
6.6.1 Shenzhen Kangtai Biological Products Corporation Information
6.6.2 Shenzhen Kangtai Biological Products Description and Business Overview
6.6.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Shenzhen Kangtai Biological Products Product Portfolio
6.7.5 Shenzhen Kangtai Biological Products Recent Developments/Updates
6.8 Serum Institute
6.8.1 Serum Institute Corporation Information
6.8.2 Serum Institute Description and Business Overview
6.8.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Serum Institute Product Portfolio
6.8.5 Serum Institute Recent Developments/Updates
7 Hepatitis B Vaccine (Recombinant) Manufacturing Cost Analysis
7.1 Hepatitis B Vaccine (Recombinant) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Hepatitis B Vaccine (Recombinant)
7.4 Hepatitis B Vaccine (Recombinant) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Hepatitis B Vaccine (Recombinant) Distributors List
8.3 Hepatitis B Vaccine (Recombinant) Customers
9 Hepatitis B Vaccine (Recombinant) Market Dynamics
9.1 Hepatitis B Vaccine (Recombinant) Industry Trends
9.2 Hepatitis B Vaccine (Recombinant) Growth Drivers
9.3 Hepatitis B Vaccine (Recombinant) Market Challenges
9.4 Hepatitis B Vaccine (Recombinant) Market Restraints
10 Global Market Forecast
10.1 Hepatitis B Vaccine (Recombinant) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Hepatitis B Vaccine (Recombinant) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Hepatitis B Vaccine (Recombinant) by Type (2022-2027)
10.2 Hepatitis B Vaccine (Recombinant) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Hepatitis B Vaccine (Recombinant) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Hepatitis B Vaccine (Recombinant) by Application (2022-2027)
10.3 Hepatitis B Vaccine (Recombinant) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Hepatitis B Vaccine (Recombinant) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Hepatitis B Vaccine (Recombinant) by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Hepatitis B Vaccine (Recombinant) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Hepatitis B Vaccine (Recombinant) Covered in This Study
Table 5. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Hepatitis B Vaccine (Recombinant) Sales Share by Manufacturers (2016-2021)
Table 7. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Hepatitis B Vaccine (Recombinant) Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Hepatitis B Vaccine (Recombinant) Manufacturing Sites and Area Served
Table 11. Manufacturers Hepatitis B Vaccine (Recombinant) Product Type
Table 12. Global Hepatitis B Vaccine (Recombinant) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Hepatitis B Vaccine (Recombinant) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatitis B Vaccine (Recombinant) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2016-2021) & (K Units)
Table 16. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2016-2021)
Table 17. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2021) & (K Units)
Table 19. North America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2016-2021)
Table 20. North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2016-2021)
Table 22. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2021) & (K Units)
Table 23. Europe Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2016-2021)
Table 24. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2016-2021)
Table 30. Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2016-2021)
Table 32. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2016-2021)
Table 38. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Type (2016-2021)
Table 39. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2016-2021)
Table 40. Global Hepatitis B Vaccine (Recombinant) Revenue (Million US$) by Type (2016-2021)
Table 41. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Type (2016-2021)
Table 42. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2016-2021)
Table 43. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Application (2016-2021)
Table 44. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2016-2021)
Table 45. Global Hepatitis B Vaccine (Recombinant) Revenue (Million US$) by Application (2016-2021)
Table 46. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Application (2016-2021)
Table 47. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2016-2021)
Table 48. GSK Corporation Information
Table 49. GSK Description and Business Overview
Table 50. GSK Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. GSK Hepatitis B Vaccine (Recombinant) Product
Table 52. GSK Recent Developments/Updates
Table 53. Merck Corporation Information
Table 54. Merck Description and Business Overview
Table 55. Merck Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Merck Hepatitis B Vaccine (Recombinant) Product
Table 57. Merck Recent Developments/Updates
Table 58. Sanofi Pasteur Corporation Information
Table 59. Sanofi Pasteur Description and Business Overview
Table 60. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product
Table 62. Sanofi Pasteur Recent Developments/Updates
Table 63. Dynavax Technologies Corporation Information
Table 64. Dynavax Technologies Description and Business Overview
Table 65. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product
Table 67. Dynavax Technologies Recent Developments/Updates
Table 68. LG Life Sciences Corporation Information
Table 69. LG Life Sciences Description and Business Overview
Table 70. LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. LG Life Sciences Hepatitis B Vaccine (Recombinant) Product
Table 72. LG Life Sciences Recent Developments/Updates
Table 73. KM Biologics Corporation Information
Table 74. KM Biologics Description and Business Overview
Table 75. KM Biologics Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. KM Biologics Hepatitis B Vaccine (Recombinant) Product
Table 77. KM Biologics Recent Developments/Updates
Table 78. Shenzhen Kangtai Biological Products Corporation Information
Table 79. Shenzhen Kangtai Biological Products Description and Business Overview
Table 80. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product
Table 82. Shenzhen Kangtai Biological Products Recent Developments/Updates
Table 83. Serum Institute Corporation Information
Table 84. Serum Institute Description and Business Overview
Table 85. Serum Institute Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Serum Institute Hepatitis B Vaccine (Recombinant) Product
Table 87. Serum Institute Recent Developments/Updates
Table 88. Production Base and Market Concentration Rate of Raw Material
Table 89. Key Suppliers of Raw Materials
Table 90. Hepatitis B Vaccine (Recombinant) Distributors List
Table 91. Hepatitis B Vaccine (Recombinant) Customers List
Table 92. Hepatitis B Vaccine (Recombinant) Market Trends
Table 93. Hepatitis B Vaccine (Recombinant) Growth Drivers
Table 94. Hepatitis B Vaccine (Recombinant) Market Restraints
Table 95. Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Type (2022-2027) & (K Units)
Table 96. Global Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Type (2022-2027)
Table 97. Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 98. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share Forecast by Type (2022-2027)
Table 99. Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Application (2022-2027) & (K Units)
Table 100. Global Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Application (2022-2027)
Table 101. Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 102. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share Forecast by Application (2022-2027)
Table 103. Global Hepatitis B Vaccine (Recombinant) Sales Forecast by Region (2022-2027) & (K Units)
Table 104. Global Hepatitis B Vaccine (Recombinant) Sales Market Share Forecast by Region (2022-2027)
Table 105. Global Hepatitis B Vaccine (Recombinant) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 106. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share Forecast by Region (2022-2027)
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hepatitis B Vaccine (Recombinant)
Figure 2. Global Hepatitis B Vaccine (Recombinant) Market Share by Type in 2020 & 2027
Figure 3. 10mcg/0.5ml Product Picture
Figure 4. 10mcg/ml Product Picture
Figure 5. Global Hepatitis B Vaccine (Recombinant) Market Share by Application in 2020 & 2027
Figure 6. Newborn
Figure 7. Adult
Figure 8. Global Hepatitis B Vaccine (Recombinant) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global Hepatitis B Vaccine (Recombinant) Market Size 2016-2027 (US$ Million)
Figure 10. Global Hepatitis B Vaccine (Recombinant) Sales 2016-2027 (K Units)
Figure 11. Global Hepatitis B Vaccine (Recombinant) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 12. Hepatitis B Vaccine (Recombinant) Sales Share by Manufacturers in 2020
Figure 13. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers in 2020
Figure 14. The Global 5 and 10 Largest Hepatitis B Vaccine (Recombinant) Players: Market Share by Revenue in 2020
Figure 15. Hepatitis B Vaccine (Recombinant) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 16. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2016-2021)
Figure 17. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region in 2020
Figure 18. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2016-2021)
Figure 19. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region in 2020
Figure 20. U.S. Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 21. Canada Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Germany Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. France Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. U.K. Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Italy Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Russia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. China Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Japan Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. South Korea Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. India Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Australia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Taiwan Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Indonesia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Thailand Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Malaysia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Philippines Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Vietnam Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Mexico Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Brazil Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Argentina Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Turkey Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Saudi Arabia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. UAE Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Sales Market Share of Hepatitis B Vaccine (Recombinant) by Type (2016-2021)
Figure 45. Sales Market Share of Hepatitis B Vaccine (Recombinant) by Application (2016-2021)
Figure 46. Sales Market Share of Hepatitis B Vaccine (Recombinant) by Application in 2020
Figure 47. Revenue Share of Hepatitis B Vaccine (Recombinant) by Application (2016-2021)
Figure 48. Revenue Share of Hepatitis B Vaccine (Recombinant) by Application in 2020
Figure 49. Manufacturing Cost Structure of Hepatitis B Vaccine (Recombinant)
Figure 50. Manufacturing Process Analysis of Hepatitis B Vaccine (Recombinant)
Figure 51. Hepatitis B Vaccine (Recombinant) Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs